1 / 31

ASSURING SAFETY OF T/CM PRODUCTS: THE MALAYSIAN EXPERIENCE

ASSURING SAFETY OF T/CM PRODUCTS: THE MALAYSIAN EXPERIENCE. Abida Syed Haq National Pharmaceutical Control Bureau Ministry of Health Malaysia. TRADITIONAL MEDICINES. In 1994, about 4000 dietary supplements and herbal products available in the USA.

jesus
Download Presentation

ASSURING SAFETY OF T/CM PRODUCTS: THE MALAYSIAN EXPERIENCE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ASSURING SAFETY OF T/CM PRODUCTS: THE MALAYSIAN EXPERIENCE Abida Syed Haq National Pharmaceutical Control Bureau Ministry of Health Malaysia

  2. TRADITIONAL MEDICINES • In 1994, about 4000 dietary supplements and herbal products available in the USA. • Today, it is estimated that there are over 29000 herbal and other natural products are available in the USA • In Malaysia, >9000 traditional medicines registered by the Drug Control Authority for use

  3. Malaysian Drug Registry

  4. TRADITIONAL MEDICINES (TM) • Generally used as health supplements and for the treatment of benign, self limiting conditions • Occasionally used to self treat serious illnesses • Products are widely advertised over the Internet and through the mass media

  5. “IT IS NATURAL, THEREFORE IT IS SAFE” • Common misnomer • Impossible to ensure that all medical interventions including traditional medicines are entirely risk-free • Numerous reports of adverse effects associated with the use of TM • Unlike pharmaceuticals, TM continue to be marketed unless, or until, proven to be unsafe

  6. SAFETY ISSUES - MALAYSIA • Products marketed with unsubstantiated claims • Adverse drug reactions e.g. Noni juice • Continued presence of unregistered products • Adulterated products • Counterfeit

  7. SAFETY ISSUES - MALAYSIA • Product registration withdrawn • Aristolochic Acid • Kava-kava • Magnolia officinalis • Adulteration • Steroids • Fenfluramine • Sibutramine • Sildenafil • Phenylpropanolamine

  8. SAFETY ISSUES - US FDA • In the past, no evaluation of herbals done • Now, taking a new approach – evaluation on available information being done to facilitate regulatory decisions being made • Products under study • Chapparal, chromium picolinate, glucosamine, melatonin, saw palmetto and shark cartilage

  9. FACTORS AFFECTING SAFETY • Intrinsic factors • Inherent toxicity, adverse effects due to overdosage, interactions, underlying risk factors • Extrinsic factors • Quality defects, misidentification, contamination, adulteration, mislabeling, improper storage

  10. PRODUCT SAFETY • Systems have to be put in place to ensure safety of all products • Responsibility of the • Manufacturers • Product owners • Regulatory authority • Practitioners • Retailers • Consumers

  11. Mission • To have only safe traditional medicines which comply with set standards of quality available in Malaysia.

  12. Vision • To be a world leader in the production of safe traditional medicines which are of quality

  13. POLICIES & STRATEGIES • Legislation • In Malaysia, all medicinal products including traditional remedies must be registered before they can be manufactured, imported, sold • Governed by • Sale of Drugs Act • Control of Drugs and Cosmetics Regulations • Poisons Act • Medicines Advertisement Act

  14. POLICIES & STRATEGIES • Regulatory • All products are evaluated for quality & safety • Paper and laboratory evaluation • Adherence to Good Manufacturing Practices • All products subjected to surveillance • Monitoring of adverse drug reactions • Monitoring of labels, information leaflets • Control of advertisements

  15. POLICIES & STRATEGIES • Education • Manufacturers • Good knowledge of plant nomenclature • Labeling of ingredients using scientific names • Botanical verification and identification of starting materials • Quality control and quality assurance procedures • Integrity and self-regulation

  16. POLICIES & STRATEGIES • Education • Practitioners of conventional medicines • Basic knowledge on traditional medicines • Break away from situation of “don’t ask, don’t tell” • Monitoring and reporting of adverse reactions • Public • Using products in accordance to intended use • Be forthcoming with information

  17. NATIONAL SURVEILLANCE PROGRAM • Ideally, all marketed products should undergo surveillance • Criteria for surveillance • Registered, marketed products which have never been tested • Products previously found to have failed lab analysis • Manufacturers identified by GMP inspectors to have problems • “Tip-offs”/suspicious products

  18. NATIONAL SURVEILLANCE PROGRAM • Quality standards • Microbial/ fungal Limit Tests • Testing of toxic heavy metal contamination i.e. lead, mercury, arsenic • Detection of adulterants/ undeclared drugs • Adverse drug reactions monitoring • Local • International

  19. NATIONAL SURVEILLANCE PROGRAM Ref: National Pharmaceutical Control Bureau

  20. NATIONAL SURVEILLANCE PROGRAM Ref: National Pharmaceutical Control Bureau

  21. Strengths • Good regulatory system • Compulsory testing as part of the registration procedure • Post-marketing Surveillance • System for investigating product complaints • Adequate laboratory testing facilities for surveillance samples

  22. Strengths • Implementation of Good Manufacturing Practices for all manufacturers of traditional medicines •  QUALITY  SAFETY • ISO 9002 certified quality system • PIC/S Certification • A good pharmacy enforcement unit

  23. PUBLIC EVALUATION & REGISTRATION SAFETY ISSUES PHARMACY ENFORCEMENT SURVEILLANCE GMP & LICENSING

  24. Weaknesses • Poor compliance to GMP by some manufacturers • Inadequate finished product testing by manufacturers • Lack of standardisation of “active” ingredients • Security/tamper-proof packaging systems

  25. Weaknesses • Underreporting of adverse reactions by health professionals, consumers • No reporting of adverse reactions by traditional medicine practitioners • Inadequate availability of information • adverse reactions of ingredients • interactions with pharmaceuticals • contraindications

  26. Opportunities • Increasing knowledge on the use of traditional medicines by health professionals • Regular dialogues with traditional medicine practitioners • More stringent regulatory requirements to ensure the quality of starting materials, formulations used • Global partnership with WHO, other regulatory and health authorities

  27. THREATS • Complacency • Unscrupulous manufacturers and traders • “Supply and Demand” for unregistered products

  28. THE PARADIGM SHIFT • Evidence on efficacy – inefficacy is also a safety issue • Evidence on the safety of products and therapies used – not sufficient to just believe that it safe • Need to have a system for assuring product safety • Better quality control of products – underdosing, overdosing, contamination, adulteration are all safety issues

  29. THE WAY FORWARD • Increased surveillance - by regulators, industry • Improved safety monitoring • System for identifying unregistered/ • counterfeit products • Good knowledge base – information hub • In-house laboratory testing by manufacturers

  30. It is an uphill task, but…. …we have already got a head start!

  31. THANK YOU TERIMA KASIH THANK YOU

More Related